Essentially, recent experimental study demonstrated that decitabine significantly enhanced anti-AML effects of CD123 CAR-T cells in vitro (THP1 cells) and in vivo (NSG mice bearing THP1 tumor xenografts). This evidence concerns the gene IL3RA and acute myeloid leukemia.